drugset / Trial / NCT02876796
Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects
RandomizedCrossoverDouble-blind
Summary
The primary objective of this study is to assess the pharmacodynamic (PD) effects of GS-0976 (NDI-010976) on fractional de novo lipogenesis (DNL) following a single oral dose administration in overweight and/or obese, but otherwise healthy, male adults.
Timeline
- Start
- 2015-08
- Primary completion
- 2015-09
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firsocostat | Small molecule | 20 mg | Oral |
| Subject | Firsocostat | Small molecule | 50 mg | Oral |
| Subject | Firsocostat | Small molecule | 200 mg | Oral |
Indications
No indication recorded.